Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates VBI Vaccines has partnered with the National Research Council of Canada (NRC) to create a pan-coronavirus vaccine candidate.
The candidate will aim to target Covid-19, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) infections caused by different coronaviruses.
VBI will offer its viral vaccine expertise, eVLP technology platform and coronavirus antigens. Meanwhile, NRC will contribute to the alliance via its Covid-19 antigens and assay development capabilities.
The partners intend to discover a vaccine candidate the most immunogenic. VBI Vaccines chief medical officer Francisco Diaz-Mitoma said: “Coronaviruses are